Table 2.
ART initiation (“Ever”), continued ART use (“On”), and viral suppression (VS) among CNICS patients in 2009 (N=4265) and 2010 (N=4637) who were ART-naïve at the time of cohort entry
| CD4 nadir ≤350 cells/mm3 | CD4 nadir 351-500 cells/mm3 | CD4 nadir >500 cells/mm3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| N | % | % | % | N | % | % | % | N | % | % | % | |
| (% total) | Ever | On | VS | (% total) | Ever | On | VS | (% total) | Ever | On | VS | |
| Total in 2009 | 3292 (100) |
96 | 91 | 74 | 563 (100) | 63 | 58 | 44 | 410 (100) | 27 | 25 | 25 |
| Total in 20101 | 3532 (100) |
97 | 94 | 73 | 660 (100) | 73 | 70 | 57 | 445 (100) | 38 | 36 | 33 |
| Gender2 | ||||||||||||
| Male | 2898 (82) | 97 | 94 | 75 | 560 (85) | 73 | 70 | 57 | 363 (82) | 43 | 41 | 35 |
| Female | 599 (17) | 97 | 92 | 68* | 98 (15) | 71 | 65 | 55 | 76 (17) | 17* | 14* | 263 |
| Age (years) | ||||||||||||
| 18-29 | 304 (9) | 95* | 89* | 64* | 142 (22) | 61* | 59* | 46* | 116 (26) | 42 | 41 | 33 |
| 30-39 | 850 (24) | 96* | 93 | 70* | 208 (32) | 75 | 72 | 57 | 122 (27) | 37 | 35 | 30 |
| 40-49 | 1400 (40) | 98 | 94 | 75 | 197 (30) | 78 | 72 | 61 | 140 (31) | 37 | 35 | 34 |
| ≥50 | 978 (28) | 98 | 95 | 77 | 113 (17) | 79 | 76 | 62 | 67 (15) | 34 | 28 | 36 |
| Race/Ethnicity2 | ||||||||||||
| Non-Hispanic White | 1618 (46) | 97 | 94 | 76 | 341 (52) | 77 | 74 | 60 | 202 (45) | 39 | 37 | 32 |
| Non-Hispanic Black | 1164 (33) | 96 | 91* | 65* | 187 (28) | 65* | 60* | 51* | 157 (35) | 34 | 30 | 35 |
| Hispanic | 520 (15) | 98 | 96 | 79 | 86 (13) | 76 | 73 | 52 | 55 (12) | 47 | 45 | 29 |
| Asian/Pacific Islander | 104 (3) | 99 | 97 | 79 | 17 (3) | 71 | 71 | 59 | 11 (2) | 45 | 45 | 36 |
| HIV Risk Category2 | ||||||||||||
| MSM | 2079 (59) | 97 | 94 | 77* | 444 (67) | 74 | 71 | 59 | 302 (68) | 43* | 41* | 34 |
| IDU (non-MSM) | 349 (10) | 96 | 90* | 65 | 45 (7) | 62 | 58 | 42 | 25 (6) | 24 | 24 | 20 |
| Heterosexual | 986 (28) | 97 | 94 | 70 | 147 (22) | 73 | 68 | 56 | 105 (24) | 24 | 20 | 29 |
| Continuous Care in 2010 | ||||||||||||
| Yes | 2978 (84) | 98 | 95 | 76 | 542 (82) | 77 | 74 | 62 | 353 (79) | 40 | 38 | 36 |
| No | 554 (16) | 95* | 86* | 59* | 118 (18) | 58* | 52* | 33* | 92 (21) | 29 | 26* | 21* |
| Total from sites reporting | ||||||||||||
| psychiatric and substance abuse data (N=3287) |
2490 (100) |
471 (100) | 326 (100) | |||||||||
| Mental Illness | ||||||||||||
| Psychosis, BPD or PD | 393 (16) | 96 | 90 | 70 | 74 (16) | 77 | 72 | 53 | 52 (16) | 27 | 21* | 35 |
| Depression/Anxiety | 1623 (65) | 97* | 93 | 73 | 306 (65) | 78 | 75 | 59 | 195 (60) | 45 | 43 | 32 |
| None of the above | 474 (19) | 96 | 92 | 70 | 91 (19) | 68 | 67 | 54 | 79 (24) | 41 | 38 | 42 |
| Substance Abuse | ||||||||||||
| Opiates | 67 (3) | 97 | 91 | 57* | 14 (3) | 71 | 71 | 57 | 9 (3) | 11 | 11 | 11 |
| Amphetamines | 122 (5) | 95 | 93 | 67 | 32 (7) | 78 | 75 | 56 | 15 (5) | 47 | 47 | 20 |
| Cocaine | 239 (10) | 94* | 87* | 59* | 51 (11) | 69 | 65 | 47 | 35 (11) | 37 | 37 | 34 |
| At-risk alcohol | 191 (8) | 97 | 93 | 71 | 40 (8) | 78 | 70 | 53 | 28 (9) | 25 | 25 | 29 |
| None of the above | 1871 (75) | 97 | 94 | 75 | 334 (71) | 77 | 74 | 59 | 239 (73) | 44 | 41 | 37 |
All following rows are CNICS patients in 2010
Categories with <50 patients in any stratum omitted from table (transgender male and female; American Indian, multiple, “other” and missing race; and “other” and missing HIV risk factor). Non-Hispanic patients who reported race as “other” were also omitted from this table.
Proportion suppressed was higher that proportion on ART due to ART discontinuation occurring after the last recorded VL in 2010 or viral suppression in the absence of ART initiation.
NOTE. Asterisk (*) denotes p<0.05 in Pearson chi-square tests. Reference groups were male gender, ≥50 years of age, Non- Hispanic white race/ethnicity, heterosexual HIV risk category, engaged in continuous care, and “none of the above” for mental illness and substance abuse.